Focus on CMV
Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.
News
Prof. Roy awarded gold medal for science
Schlieren, 24 January 2012
Prof. Polly Roy, scientific advisor to Redbiotec in the field of VLPs and antibodies for infectious diseases and cancer, has been awarded with one of India’s most prestigious academic awards. 
Redbiotec and DKFZ extend collaboration
Schlieren, 17 January 2012
The German Cancer Research Institute (DKFZ) and Redbiotec have extended their collaboration in the field of HPV, which started in 2009. Goal of the collaboration is the validation of chimeric VLPs, containing proteins of different serotypes on one VLP.
More children have disabilities due to congenital CMV than genetic disorders (Down syndrome).
Learn more about our proprietary rePAXTM technology.
Find our newest scientific publications here.
Meet us at one of our upcoming events.